Development of PRAME in the diagnosis and treatment of children acute leukemia
10.3760/cma.j.issn.1673-4408.2010.04.006
- VernacularTitle:PRAME在儿童急性白血病诊疗中的研究进展
- Author:
Ying NIE
- Publication Type:Journal Article
- Keywords:
PRAME;
Minimal residual disease;
Immunotherapy;
Methylation
- From:
International Journal of Pediatrics
2010;37(4):352-354
- CountryChina
- Language:Chinese
-
Abstract:
The gene of preferentially expressed antigen of melanoma(PRAME) is a gene marker of leukemia,which can be used to monitor the minimal residual disease,and can make us to comprehend the curative effect,prognosis,the grade of risk and can predict relapse.In addition,PRAME as a human tumour antigen,can be recognized by autologous cytolytic T lymphocytes,is a ideal target of immunotherapy in leukemia,and investigate the methylation level of PRAME gene CpG island,which can help us comprehend the relation of the mechanism of PRAME and leukemia.
